|
Mr. Wiley has over ten years of commercial oncology experience with a variety of products including Taxotere®, Velcade®, Oncaspar®, Gliadel Wafer® and Anzemet®. Previously he served as Associate Director, Market Planning and Development at Millennium Pharmaceuticals where he focused on strategic and pre-market planning for Velcade in emerging indications. Mr. Wiley's previous experience includes a diverse 12 year tenure at Aventis Pharmaceuticals (now Sanofi-Aventis), including management positions in marketing, national accounts & sales. In his most recent position as Senior Manager, Oncology Networks he developed and implemented contracting strategies for over $900 million in annual oncology product sales for Taxotere, and Anzemet. He was also instrumental in the successful launch of Taxotere in the non-small cell lung cancer (NSCLC) market. Mr. Wiley received a BA from The Pennsylvania State University and completed graduate level coursework at the University of New Mexico. | 